Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets World first study utilizing Somalogic...
Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals...
Primary endpoint met with confirmation of drug’s safety and tolerability Strong effects on secondary endpoints on activity markers and disease...
Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate...
ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology PR Newswire TOORAK, Australia, Sept. 22, 2014 TOORAK...
ATL1103 Phase II Trial - Successful Efficacy Results - Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels...
ATL1103 Acromegaly Phase II Trial Dosing Completed -Primary efficacy results on track to be received by end of August 2014 PR Newswire TOORAK...
ATL1102 for MS - Toxicology Study Main Findings PR Newswire TOORAK, Australia, April 1, 2014 TOORAK, Australia, April 1, 2014 /PRNewswire/...
ATL1103 Acromegaly Phase II Trial Recruitment Completed - 24 patients now recruited into the trial - 16 patients have completed dosing - No...
ATL1102 for Stem Cell Mobilisation Trial Commencement PR Newswire TOORAK, Australia, March 17, 2014 TOORAK, Australia, March 17, 2014...
Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014 PR Newswire SAN FRANCISCO, Jan. 7, 2014 SAN FRANCISCO, Jan. 7, 2014...
Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial PR Newswire TOORAK, Australia, Dec. 23, 2013 TOORAK, Australia, Dec...
ANP to present at and attend major US investment, partnering and industry conferences PR Newswire TOORAK, Australia, Aug. 28, 2013 TOORAK...
Teva Pharmaceutical Industries Ltd. (NASDAQ: Teva) and Antisense Therapeutics Ltd. (ASX: ANP) announced today that ATL/TV1102, a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.